MX2021013507A - Proceso para la preparacion de inhibidores del canal de cloruro ciec-1. - Google Patents

Proceso para la preparacion de inhibidores del canal de cloruro ciec-1.

Info

Publication number
MX2021013507A
MX2021013507A MX2021013507A MX2021013507A MX2021013507A MX 2021013507 A MX2021013507 A MX 2021013507A MX 2021013507 A MX2021013507 A MX 2021013507A MX 2021013507 A MX2021013507 A MX 2021013507A MX 2021013507 A MX2021013507 A MX 2021013507A
Authority
MX
Mexico
Prior art keywords
chloride channel
clc
preparation
channel inhibitors
formula
Prior art date
Application number
MX2021013507A
Other languages
English (en)
Inventor
Nicholas Kelly
Michael John Mckenzie
Original Assignee
Nmd Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nmd Pharma As filed Critical Nmd Pharma As
Publication of MX2021013507A publication Critical patent/MX2021013507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Abstract

Esta divulgación se relaciona con un proceso químico mejorado para fabricar compuestos que son inhibidores del canal de cloruro de ClC-1.
MX2021013507A 2019-06-19 2020-06-19 Proceso para la preparacion de inhibidores del canal de cloruro ciec-1. MX2021013507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181262 2019-06-19
PCT/EP2020/067065 WO2020254554A1 (en) 2019-06-19 2020-06-19 Process for the preparation of clc-1 chloride channel inhibitors

Publications (1)

Publication Number Publication Date
MX2021013507A true MX2021013507A (es) 2021-12-10

Family

ID=66999603

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013507A MX2021013507A (es) 2019-06-19 2020-06-19 Proceso para la preparacion de inhibidores del canal de cloruro ciec-1.

Country Status (15)

Country Link
US (1) US20220298124A1 (es)
EP (1) EP3986878A1 (es)
JP (1) JP2022537493A (es)
KR (1) KR20220022895A (es)
CN (1) CN113993852A (es)
AR (1) AR119198A1 (es)
AU (1) AU2020298092A1 (es)
BR (1) BR112021025588A2 (es)
CA (1) CA3137672A1 (es)
IL (1) IL287901A (es)
MX (1) MX2021013507A (es)
SG (1) SG11202111122RA (es)
TW (1) TW202115003A (es)
WO (1) WO2020254554A1 (es)
ZA (1) ZA202107653B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024068862A1 (en) 2022-09-30 2024-04-04 Nmd Pharma A/S Compositions and methods for treating myasthenia gravis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2879826T3 (es) 2015-06-15 2021-11-23 Nmd Pharma As Compuestos para su uso en el tratamiento de trastornos neuromusculares
TWI780281B (zh) * 2017-12-14 2022-10-11 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物

Also Published As

Publication number Publication date
SG11202111122RA (en) 2021-11-29
CA3137672A1 (en) 2020-12-24
AU2020298092A1 (en) 2021-11-18
TW202115003A (zh) 2021-04-16
US20220298124A1 (en) 2022-09-22
JP2022537493A (ja) 2022-08-26
CN113993852A (zh) 2022-01-28
BR112021025588A2 (pt) 2022-02-01
AR119198A1 (es) 2021-12-01
WO2020254554A1 (en) 2020-12-24
IL287901A (en) 2022-01-01
EP3986878A1 (en) 2022-04-27
ZA202107653B (en) 2023-05-31
KR20220022895A (ko) 2022-02-28

Similar Documents

Publication Publication Date Title
MX2023000081A (es) Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor.
MX2023007581A (es) Analogos de rapamicina unidos a c26 como inhibidores de mtor.
PH12019501842A1 (en) Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MX2019013031A (es) Análogos de rapamicina como inhibidores de mtor.
PH12016501633B1 (en) Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MX2020004504A (es) Derivados de fenoximetilo.
MX2018001430A (es) Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
PH12018500409A1 (en) New bicyclic compounds as dual atx/ca inhibitors
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
MX2022005726A (es) Sintesis mejorada del compuesto inhibidor de g12c de kras.
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
MX2021000348A (es) 2-fluoro-3-nitrotolueno cristalino y procedimiento para la preparacion del mismo.
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
PH12018550165A1 (en) An improved process for the preparation of butorphanol tartrate
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2017005988A (es) Compuestos intermediarios para la produccion de ingredientes perfumantes.
MX2021013507A (es) Proceso para la preparacion de inhibidores del canal de cloruro ciec-1.
MX2019009242A (es) Un proceso novedoso para la sintesis de 1-aril-1-trifluoro-metil-c iclopropanos.
MX2022001167A (es) Metodo para el tratamiento de una composicion que comprende vainillina natural.
MX2021004996A (es) Preparacion de 4-metiltetrahidropiranos 2-sustituidos a partir de 4-hidroxi-4-metiltetrahidropiranos 2-sustituidos como materiales de partida.
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
MX2022007190A (es) Analogos de cistina diamida para la cistinuria.
MX2022006178A (es) Composiciones que comprenden tricianohexano.
MX2021008323A (es) Preparacion de 5-aril pentanoles.